{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.919","upperLimit":"1.00","value":"0.969"},{"groupId":"OG001","lowerLimit":"0.913","upperLimit":"0.986","value":"0.949"},{"groupId":"OG002","lowerLimit":"0.928","upperLimit":"0.993","value":"0.96"},{"groupId":"OG003","lowerLimit":"0.862","upperLimit":"0.954","value":"0.907"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"108"},{"groupId":"OG003","value":"113"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from randomization/assignment of post-surgical treatment to the appearance of lesions, including primary, nodal or new site, or death, whichever occurs first. These patients are considered disease-free after surgery so the appearance of any lesions is counted as progression. Kaplan-Meier estimate was used to characterize progression-free survival rate at 2 years.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.","id":"OG000","title":"Arm S (Surgery) Then Arm A (Low Risk, Observation)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.","id":"OG001","title":"Arm S (Surgery) Then Arm B (Intermediate Risk, Low-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.","id":"OG002","title":"Arm S (Surgery) Then Arm C (Intermediate Risk, Standard-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.","id":"OG003","title":"Arm S (Surgery) Then Arm D (High Risk, IMRT, Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years","title":"Progression-free Survival Rate at 2 Years","type":"PRIMARY","unitOfMeasure":"proportion of participants"}